Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Mod Rheumatol ; 27(2): 364-368, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25619281

RESUMEN

A 37-year-old woman with rheumatoid arthritis and interstitial lung disease (ILD) developed clinically amyopathic dermatomyositis (CADM) after achieving pregnancy through in vitro fertilization. She was given oral prednisolone, which improved her respiratory status, and delivered a healthy baby at 35 weeks' gestation. There are few reports of successful outcomes for CADM during pregnancy; to the best of our knowledge, this is the first report of successful delivery in a patient with both CADM and ILD.


Asunto(s)
Dermatomiositis/diagnóstico , Enfermedades Pulmonares Intersticiales/diagnóstico , Complicaciones del Embarazo/diagnóstico , Adulto , Dermatomiositis/complicaciones , Femenino , Humanos , Nacimiento Vivo , Enfermedades Pulmonares Intersticiales/complicaciones , Embarazo
2.
Mod Rheumatol ; 26(6): 956-957, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25036234

RESUMEN

The diagnosis of macrophage activation syndrome (MAS) in patients with systemic lupus erythematosus (SLE) may be challenging as it can mimic the clinical features of the underlying disease or be confused with an infectious complication. In this report, a Japanese woman in her forties had diverse clinical features of MAS at initial presentation of SLE, where erythematosus plaques with histiocytic infiltrates focally surrounding degenerated collagen might be the earliest indicator of MAS.


Asunto(s)
Lupus Eritematoso Sistémico/complicaciones , Síndrome de Activación Macrofágica/patología , Macrófagos/patología , Adulto , Femenino , Humanos , Lupus Eritematoso Sistémico/patología , Síndrome de Activación Macrofágica/complicaciones
3.
Clin Immunol ; 161(2): 333-8, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26387628

RESUMEN

Systemic sclerosis (SSc) is a multi-organ fibrotic disease that affects the skin and various internal organs. Therapeutic strategies for tissue fibrosis have not been established; however, aberrantly activated fibroblasts in affected lesions are key targets for modulating fibrosis. Recently, increased intracellular cyclic GMP (cGMP) levels were demonstrated to improve fibrosis levels in various diseases. The purpose of this study was to assess the anti-fibrotic properties of cGMP in cultured fibroblasts from patients with SSc. The phosphodiesterase (PDE) 5 inhibitor sildenafil increased the intracellular cGMP levels in skin fibroblasts in a dose-dependent manner. Sildenafil treatment also significantly decreased the expression of several pro-fibrotic factors that were upregulated by TGF-ß1 treatment in SSc skin fibroblasts. These inhibitory effects occurred via non-canonical TGF-ß signaling. Our findings revealed that sildenafil might be a novel strategy to treat tissue fibrosis and vasculopathy in SSc.


Asunto(s)
GMP Cíclico/metabolismo , Fibroblastos/efectos de los fármacos , Citrato de Sildenafil/farmacología , Piel/patología , Adulto , Anciano , Western Blotting , Células Cultivadas , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Cadena alfa 1 del Colágeno Tipo I , Factor de Crecimiento del Tejido Conjuntivo/genética , Factor de Crecimiento del Tejido Conjuntivo/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Fibroblastos/metabolismo , Fibrosis/prevención & control , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de Fosfodiesterasa 5/farmacología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Esclerodermia Sistémica/genética , Esclerodermia Sistémica/metabolismo , Esclerodermia Sistémica/patología , Piel/metabolismo , Factor de Crecimiento Transformador beta1/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA